This content is machine translated Venous thromboembolism prevention PCSK9 inhibitors: Current evidence, mechanisms and unanswered questions Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of cardiovascular mortality worldwide after myocardial infarction and stroke. Despite continuous...…
View Post 5 min This content is machine translated LDL cholesterol level On the way to the (LDL-C) target Cardiovascular disease ( CVD) is the leading cause of death worldwide. Lowering the level of LDL cholesterol (LDL-C) in the blood reduces the risk of CVD such as heart attacks…
View Post 6 min This content is machine translated Risk management for diabetes and severe mental illness Critically question statin prescribing in patients with T2D and SMI Differences in mental health outcomes in diabetic patients with concomitant severe mental illness are often associated, at least in part, with suboptimal cardiovascular risk monitoring. A Dutch-Scottish research group investigated…
View Post 3 min This content is machine translated LDL cholesterol Bempedoic acid and cardiovascular outcomes in statin intolerant patients Treatment of elevated LDL cholesterol levels is a central component of modern therapy to reduce the risk of serious cardiovascular events in patients with primary or secondary prevention. However, 7%…
View Post 3 min This content is machine translated Dyslipidemia Effective lipid management – lipid apheresis as a last resort? Current European guidelines advocate strict LDL-C lowering to prevent cardiovascular disease. Statins, which can significantly lower both total and LDL cholesterol, play a central role. In addition, PCSK9 inhibitors achieve…
View Post 4 min This content is machine translated Hypercholesterolemia Bempedoic acid closes “gap” in lipid-lowering field Treatment with statins is part of the standard therapy for high cholesterol levels. However, a substantial proportion of patients on statin therapy alone do not achieve the LDL-C levels specified…
View Post 3 min This content is machine translated Blood pressure and lipid management Effects of effective therapy on cardiovascular health. A major factor in the development of atherosclerotic-related cardiovascular disease is the retention and accumulation of cholesterol-rich lipoproteins in the vessels. Therefore, in addition to adequate blood pressure control, the…
View Post 4 min This content is machine translated Lipid management: LDL cholesterol reduction Add-on to statin therapy recommended in patients at high cardiovascular risk Numerous empirical studies confirm that there is a causal relationship between high LDL cholesterol levels and cardiac events. The current motto with regard to LDL cholesterol reduction is “the lower,…
View Post 3 min This content is machine translated Lipid Management Cardiovascular prevention = effective cholesterol reduction Lipid-lowering agents have been used for years for both primary and secondary prevention of cardiovascular disease. Statins, which can significantly lower both total and LDL cholesterol, play a central role.…
View Post 4 min This content is machine translated Annual European Congress of Rheumatology (EULAR) 2018, Amsterdam Regular physical activity at the heart of osteoarthritis management “Preventing osteoarthritis is possible!” was the title of a symposium at the European League Against Rheumatism (EULAR) 2018 Annual Congress in Amsterdam. Recognize languageAfrikaansAlbanianAmharicArabicArmenianAzerbaijaniBasqueBengaliBurmeseBosnianBulgarianCebuanoChichewaChinese tradChinese verDanishGermanEnglishEsperantoEstonianFilipinoFinnishFrenchFrisianGalicianGeorgianGreekGujaratiHaitianHausaHawaiianHebrewHindiHmongIgboIndonesianIrishIcelandicItalianJapaneseJavaneseYiddishKannadaKazakhCatalanKhmerKyrgyzKoreanCorsicanCroatianKurdishLaoLatinLatvianLithuanianLuxembourgishMalagasyMalayalamMalaysianMalteseMaoriMarathiMacedonianMongolianNepaleseDutchNorwegianPashtoPersianPolishPortuguesePunjabiRomanianRussianSamoanScottish GaelicSwedishSerbianSesothoShonaSindhiSinhalaSlovakSlovenianSomaliSpanishSwahiliSundaneseTajikTamilTeluguThaiCzechTurkishUkrainianHungarianUrduUzbekVietnameseWelshBelarusianXhosaYorubaZulu AfrikaansAlbanianAmharicArabicArmenianAzerbaijaniBasqueBengaliBurmeseBosnianBulgarianCebuanoChichewaChinese tradChinese…
View Post 5 min This content is machine translated Swiss Society of Cardiology Joint Annual Meeting 2018, Basel Advances in atherosclerosis therapy The PCSK9 inhibitors evolocumab and alirocumab can be used successfully to lower LDL cholesterol, as shown by large outcome studies. Whether anti-inflammation can also prophylactically reduce cardiovascular risk has been…
